These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 22690482)
21. Role of biological agents in immune-mediated inflammatory diseases. Efthimiou P; Markenson JA South Med J; 2005 Feb; 98(2):192-204. PubMed ID: 15759950 [TBL] [Abstract][Full Text] [Related]
22. [Anti-cytokines in the treatment of inflammation]. Mariette X Rev Prat; 2003 Mar; 53(5):507-11. PubMed ID: 12722608 [TBL] [Abstract][Full Text] [Related]
23. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and their clinical implications. Shachar I; Karin N J Leukoc Biol; 2013 Jan; 93(1):51-61. PubMed ID: 22949334 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic human monoclonal antibodies in inflammatory diseases. Kotsovilis S; Andreakos E Methods Mol Biol; 2014; 1060():37-59. PubMed ID: 24037835 [TBL] [Abstract][Full Text] [Related]
25. [Therapeutic antibody: new opportunity for immunity and inflammatory diseases]. Sun W; Lin H; Hua F; Hu ZW Yao Xue Xue Bao; 2012 Oct; 47(10):1306-16. PubMed ID: 23289142 [TBL] [Abstract][Full Text] [Related]
26. Systemic lupus erythematosus and other autoimmune rheumatic diseases: challenges to treatment. Murphy G; Lisnevskaia L; Isenberg D Lancet; 2013 Aug; 382(9894):809-18. PubMed ID: 23972423 [TBL] [Abstract][Full Text] [Related]
31. Autoimmune diseases are connected with disturbances in cytokine synthesis, and therapy with IFN-gamma blockers is their main pathogenetic treatment. Skurkovich B; Skurkovich S Ann N Y Acad Sci; 2007 Aug; 1109():167-77. PubMed ID: 17785303 [TBL] [Abstract][Full Text] [Related]
33. The IgG molecule as a biological immune response modifier: mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory disorders. Ballow M J Allergy Clin Immunol; 2011 Feb; 127(2):315-23; quiz 324-5. PubMed ID: 21185071 [TBL] [Abstract][Full Text] [Related]
34. New treatments for SLE: cell-depleting and anti-cytokine therapies. Anolik JH; Aringer M Best Pract Res Clin Rheumatol; 2005 Oct; 19(5):859-78. PubMed ID: 16150407 [TBL] [Abstract][Full Text] [Related]
35. Therapeutic targeting of B cells for rheumatic autoimmune diseases. Engel P; Gómez-Puerta JA; Ramos-Casals M; Lozano F; Bosch X Pharmacol Rev; 2011 Mar; 63(1):127-56. PubMed ID: 21245206 [TBL] [Abstract][Full Text] [Related]
36. Cell-surface and cytokine biomarkers in autoimmune and inflammatory diseases. O'Hara RM; Benoit SE; Groves CJ; Collins M Drug Discov Today; 2006 Apr; 11(7-8):342-7. PubMed ID: 16580976 [TBL] [Abstract][Full Text] [Related]
38. Neutralization of macrophage migration inhibitory factor-novel approach for the treatment of immunoinflammatory disorders. Cvetkovic I; Stosic-Grujicic S Int Immunopharmacol; 2006 Oct; 6(10):1527-34. PubMed ID: 16919824 [TBL] [Abstract][Full Text] [Related]
39. [The current outlook in the therapy of autoimmune diseases]. Sebastiani GD; Passiu G Ann Ital Med Int; 1992; 7(2):95-101. PubMed ID: 1467130 [TBL] [Abstract][Full Text] [Related]
40. Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease. Prete M; Perosa F; Favoino E; Dammacco F Clin Exp Med; 2005 Dec; 5(4):141-60. PubMed ID: 16362794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]